Revenue of $2.51M (-7.4% Y/Y) misses by $0.33M. Cash, cash equivalents, and certificates of deposit at the end of the fiscal year ended June 30, 2022 totaled $55.9 million and the company had no long-term debt. Stockholders’ equity at the end of the fiscal year ended June 30, 2022 totaled $61.3 million. Entered into a definitive agreement to acquire Viewpoint Molecular Targeting.